You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 11676 results
  1. Rusalatide Acetate (TP508) Mitigation Effect on Radiation Induced Keratopathy

    SBC: AFFIRMED PHARMA, LLC            Topic: NEI

    Abstract Radiation induced keratopathy results in significant ocular surface disease, stem cell deficiency, vision loss, discomfort, and subsequent poor quality of life, affecting up to 23% of patients receiving radiation therapy for head and neck malignancies [1]. Studies have pointed out functional roles of corneal neurons and secretory cells of the lacrimal gland in the etiology of radiation in ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Combinations of Natural Product Compounds for Treatment of Alzheimer Disease and Related Dementias

    SBC: Path Biotech, LLC            Topic: NIA

    PROJECT SUMMARY/ABSTRACT In response to National Institute on Aging's (NIA) strategic plan and PAS-19-317, we propose novel therapeuticsto treat Alzheimer disease and related dementias (ADRDs). We have developed novel combinations of three natural product compounds, which modulate complementary pathways in multiple types of CNS cells (i.e., neurons, microglia) associated with AD pathology. These c ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Chemical-based Nitric Oxide Gas-generating Drug Device for the Treatment of Pulmonary Hypertension

    SBC: INOVODEL, INC.            Topic: NHLBI

    SUMMARY Patients with pulmonary hypertension (PH) experience low oxygen saturation, shortness of breath, low quality of life, and a short life span (lt10 years) following diagnosis. These patients frequently present to emergency rooms, and many are admitted to intensive care units (ICUs), straining the health care system. Despite therapy with phosphodiesterase-5 inhibitors, prostacyclin analogs, a ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Evaluating the efficacy of Butyric acid pro-drug nanoparticle in retinal neuroprotection

    SBC: Nutriforward, LLC            Topic: 100

    Project Summary Choroidal neovascularization (CNV) occurs in both age-related macular degeneration (AMD) and diabetic retinopathy (DR). While anti-VEGF treatment has improved the visual outcome considerably, they are far from achieving a 100% success rate (non-responsiveness between 8 and 50%). Inherited retinal degenerations (IRDs) are a group of heterogeneous, progressive, visually debilitating ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development of drug conjugates of R-spondin peptibodies for the treatment of colorectal cancer

    SBC: WNTRIX INC            Topic: 102

    PROJECT SUMMARY Colorectal cancer is still a major cause of cancer-related death in the world and only a small subset of patients benefits from therapy by immune checkpoint inhibitors. Antibody–drug conjugates (ADCs) are monoclonal antibodies (mAbs) that are covalently linked to cell-killing drugs and have emerged as a major modality in anti-cancer treatment. This approach combines high specific ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Developing RNA therapeutics for rare neurodevelopmental disorders

    SBC: Dayi Therapeutics, Inc.            Topic: NICHD

    PROJECT SUMMARY Developing RNA therapeutics for rare neurodevelopmental disorders Monogenic diseases caused by mutations in single genes are individually rare, but collectively common affecting 10% of the world population. Many of these diseases are disabling or even life threatening with no available treatment. The underlying molecular mechanisms vary. Both loss of gene function and gain of toxic ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Selective targeting of high affinity alpha4 integrins as a safe treatment strategy for IBD

    SBC: Aviara Pharmaceuticals, Inc.            Topic: 300

    Inflammatory bowel disease (IBD) is comprised mainly of Crohn’s Disease (CD) and Ulcerative Colitis (UC), and is characterized by a chronic non-resolving inflammatory response in the intestinal mucosa. Although the exact etiology is unknown, dysbiosis, genetic, environmental, and immunologic factors are all thought to play roles in this multifactorial disease. There are no cures, and in most cas ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of an Educational Product for Accelerating Solutions for Commercialization and Entrepreneurial Development (ASCEND) in Western IDeA States

    SBC: NEW MEXICO START-UP FACTORY II LLC            Topic: NIGMS

    Project Summary As a participant in the new IDeA Regional Entrepreneurship Development (I-RED) program, the goal of this proposal is to create an educational product to promote entrepreneurism and commercialization in the Mountain West region of IDeA states. The educational product and overall program are intended to address the needs of IDeA state academic institutions in developing and strengthe ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Developing a new aspiration catheter solution for the treatment of large and medium vessel occlusions

    SBC: ANEUVAS TECHNOLOGIES INC            Topic: 104

    Project Summary/Abstract Stroke is the leading cause of serious long-term disability and accounts for 4.6 million disabled people in the United States. Stroke-related costs total over $46 billion in the United States each year.1 Of the nearly 800,000 Americans who have a stroke per year, 87% experience ischemic stroke1, of which 49%-86% are attributed to either large vessel occlusions (LVO) or med ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Biomarkers for Brain Resetting as an Assistive Tool in the Treatment of Status Epilepticus

    SBC: Epifocus LLC            Topic: 104

    The proposed phase-I STTR research is an interdisciplinary effort to develop more effective clinical management of Status Epilepticus (SE) in collaboration with one of the leading neurological institutes in the world, the Barrow Neurological Institute in Phoenix, Arizona. SE is a life-threatening neurological emergency that can occur without warning and is characterized by recurrent seizures witho ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government